抗CEA单克隆抗体在卵巢癌病人体内的血药动力学研究  

BIOKINETICS OF MONOCLONAL ANTIBODIES AGAINST CEA IN OVARIAN CANCER PATIENTS

作　　者：李贵平[1] 康福[1] 胡立宽[1] 张一帆[1] 贾士铨[1] 

机构地区：[1]核医学教研室

出　　处：《山东医科大学学报》1993年第2期109-112,共4页Acta Academiae Medicinae Shandong

摘　　要：研究了^(131)I-CEA C50在22例卵巢癌病人放射免疫显像中的血药动力学特性。^(130)I-C50的血半清除时间平均为T1/2α=24.8h,T1/2β=40.5h(n=12)。在静脉给药后28h内约有给予放射性总剂量的50%由尿排出。循环血液中标记抗体主要在血浆中。卵巢癌病人在接受静注标记抗体后2～3周即可产生人抗鼠抗体,在体内维持至少9个月以上。二次显像应用时,抗鼠抗体的产生影响了二次显像效果,限制了鼠源性单抗的反复应用。The biokinetics of ^(131)i-labelled monoclonal antibodies against CEA have been examined in 22 ovarian cancer patients who were receiving labelled antibody in diagnostic immunoscintigraphy trials.A hi-phasic decline of radiolabelled preparations was measured with initial half-lives 24.8 hours and then with 40.5 hours in second half-lives.Blood-borne radioactivity was associated predominantly with plasma rather than cellular elements.Urinary excretion of radioactivity was about 50% of injected dose in the first 28 hours. However,anti-mouse-IgG antibody(HAMA)detected 14 days after admini- stration of radiolabelled antibody and was present for at least 9 months, and has implications for the efficiency of repeated image studies.

关 键 词：卵巢肿瘤 癌胚抗原 单克隆抗体 

分 类 号：R737.310.2[医药卫生—肿瘤]